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A

vailability and accessibility to cancer medications is of great concern for developing
countries and contributes negatively to the survival
rates of cancer patients. Although there are major
challenges involved in obtaining the drugs for
curative, supportive, and palliative care in many
countries, these shortages are not well documented
[1,2]. In 2016, we attempted to describe the availability of pediatric cancer medications in Armenia,
which are listed in the World Health Organization
Model List of Essential Medicines [2]. The survey
included 64 agents, including antineoplastic drugs,
antimicrobials, and medications for supportive care.
The study showed that certain drugs from the SIOP
PODC (Pediatric Oncology in Developing Countries
committee of the International Society of Pediatric
Oncology) Essential Medication List for pediatric
oncology were not ofﬁcially registered and available
in Armenia (Table 1). Accordingly, only 22 of 30
(73%) antineoplastic drugs were ofﬁcially registered
in Armenia; of these, 18% drugs were not available
when conducting the study. The study results were
published in the past year and our goal was to
inform the ofﬁcials about the gaps and to help
develop effective policies in order to prevent similar
situations in the future [2,3].
Recently, we were experiencing a shortage of
several critically important medications; therefore, a

follow-up study was initiated to assess if and how
the concern is addressed.
In October 2019, we conducted a survey through
an interviewer-administered checklist within three
main pharmacies located in Yerevan, Armenia,
which import essential pediatric cancer medications
and asked the same questions as in the previous
study, that is, whether the mentioned medications
are ofﬁcially registered and available at that
moment. Subsequently, we double-checked the results with the Ministry of Health of the Republic of
Armenia.
Table 1 summarizes the results of the survey
compared with the data of the previous study.
The data matched with the Ministry of Health,
and pharmacies reported that 16 of 30 (53%)
essential antineoplastic drugs were not registered in
Armenia at the time of conducting the survey. These
nonregistered drugs were Asparaginase, Bleomycin,
Dacarbazine, Dactinomycin, Daunorubicin, Hydroxyurea, Ifosfamide, Mercaptopurine, Thioguanine, Vinblastine, Vincristine, all-trans retinoic
acid (ATRA), 13-cis-retinoic acid, Busulfan,
Melphalan, and Topotecan. The analysis also indicated that eight of 30 (26.7%) cancer drugs (Carboplatin, Hydroxyurea, Thioguanine, ATRA, 13-cisretinoic acid, Busulfan, Melphalan, and Vinorelbine)
were not available at the time of conducting the
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Table 1. Availability and registration status of essential medications for the treatment of childhood cancer in Armenia.

Dark and light red e the drug was not available and/or registered in 2016 and 2019, respectively.
Dark and light blue e morphine was not available in the pharmacies, but was available in hospitals.
*It worth to mention, that oral morphine, which was not available in the country in the past, currently is available.

survey. Imatinib was available as a charity from the
MAX International Foundation.
Only four (21%) in the list of 19 antimicrobials
were not registered (Amphotericin B, Caspofungin,
Ganciclovir, and Voriconazole). At the time of conducting this survey, three (15.8%) were not available
(Amphotericin B, Caspofungin, and Voriconazole).
Among the medications for supportive care, only
Codeine, Docusate, Folinic acid, and Mesna were
not registered in Armenia, whereas among the
nonregistered supportive care agents, only Codeine
was not available at the time of conducting the
survey.
Accordingly, the study showed that the number of
ofﬁcially registered medications (antineoplastic
agents) signiﬁcantly decreased from 73% in 2016 to
47% in 2019.
The majority of the above mentioned nonregistered anticancer agents (Asparaginase, Bleomycin,
Mercaptopurine,
Ifosfamide,
and
Vincristine) are considered to be commonly used in
the treatment regimens of different pediatric cancers. Furthermore, lack of registered anticancer
agents in the market poses difﬁculties in the delivery of appropriate cancer care.
Armenia is a small country with a population of 3
million. Annually, approximately 8500 adult and
80e100 new pediatric cancer cases are reported. A
relatively small market is one of the reasons why
pharmaceutical companies are not interested in

registering the drugs in Armenia. Though there are
several initiatives to simplify the registration process of orphan drugs in Armenia, the problem still
exists and the situation is increasingly becoming
worse.
Other reasons that might contribute to the cause
include the shortages of certain drugs in the international market, different gaps in supply chain, lack
of prioritization of pediatric cancer by the authorities, and limited centralized procurement of the
pediatric cancer drugs. In Armenia, every child with
cancer, regardless of their ﬁnancial capabilities, receives appropriate care which is covered mostly by
the charitable foundations (>80%). The absence of
registration of certain medications poses serious
obstacles for the foundations to procure the drugs as
well.
Available evidence suggests that nonregistered
drugs are mostly unavailable and unaffordable for
the patients [2]. Despite the availability of some of
the nonregistered drugs in the market, lack of ofﬁcial registration makes it difﬁcult to evaluate the
quality and safety of those medications.
Our follow-up research aims to raise the awareness about this important issue and help the ofﬁcials
address this critical need. In our opinion, some of
the ways to resolve these issues include the prioritization of pediatric cancer, centralized procurement
of these drugs by the government, and cooperation
with international organizations and other countries
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possibly to make a joint purchase for certain medications. Other countries with limited resources may
also be facing similar problems, and further
research from different regions can set a ground for
international framework to address this critical
challenge.
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